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Abstract
Clinical trial transparency forms the foundation of evidence-based medicine, and trial sponsors, especially publicly
funded institutions such as universities, have an ethical and scientific responsibility to make the results of clinical
trials publicly available in a timely fashion. We assessed whether the thirty UK universities receiving the most
Medical Research Council funding in 2017–2018 complied with World Health Organization best practices for clinical
trial reporting on the US Clinical Trial Registry (ClinicalTrials.gov). Firstly, we developed and evaluated a novel
automated tracking tool (clinical-trials-tracker.com) for clinical trials registered on ClinicalTrials.gov. This tracker
identifies the number of due trials (whose completion lies more than 395 days in the past) that have not reported
results on the registry and can now be used for all sponsors. Secondly, we used the tracker to determine the
number of due clinical trials sponsored by the selected UK universities in October 2020. Thirdly, using the FDAAA
Trials Tracker, we identified trials sponsored by these universities that are not complying with reporting
requirements under the Food and Drug Administration Amendments Act 2007. Finally, we quantified the average
and median number of days between primary completion date and results posting. In October 2020, the
universities included in our study were sponsoring 1634 due trials, only 1.6% (n = 26) of which had reported results
within a year of completion. 89.8% (n = 1468) of trials remained unreported, and 8.6% (n = 140) of trials reported
results late. We also identified 687 trials that contained inconsistent data, suggesting that UK universities often fail
to update their data adequately on ClinicalTrials.gov. The mean reporting delay after primary completion for trials
that posted results was 981 days, the median 728 days. Only four trials by UK universities violated the FDAAA 2007.
We suggest a number of reasons for the poor reporting performance of UK universities on ClinicalTrials.gov: (i)
efforts to improve clinical trial reporting in the UK have to date focused on the European clinical trial registry
(EU CTR), (ii) the absence of a tracking tool for timely reporting on ClinicalTrials.gov has limited the visibility of
institutions’ reporting performance on the US registry and (iii) there is currently a lack of repercussions for UK
sponsors who fail to report results on ClinicalTrials.gov which should be addressed in the future.
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Introduction
‘Do no harm’ is a fundamental principle governing med-
ical practice. In order to provide the best care for pa-
tients, clinicians and healthcare guideline providers must
have the necessary information to make evidence-based
decisions. Clinical trial sponsors therefore have an eth-
ical and scientific obligation to provide complete infor-
mation about the efficacy and safety of health
technologies. The World Health Organization (WHO)
recommends that trial sponsors make the key outcomes
of all clinical trials available on the registry where they
were originally registered within 12months of study
completion [1]. However, despite global efforts to com-
bat delayed or incomplete reporting of clinical trials, re-
sults often remain unpublished, particularly if ‘negative’
or not statistically significant [2]. The COVID-19 pan-
demic has further stimulated calls for ‘radical transpar-
ency’ and brought the attention of the global scientific
community to the issue of transparent and timely
reporting of trial results [3]. Notably, clinical trial regis-
tries offer the opportunity to share results faster and, in
more detail, than peer-reviewed journals do [4].
On 29 July 2020, the NHS Health and Research Au-
thority released a new strategy to promote transparency
and openness in health and social care research in the
UK, in which it highlighted that 30% of clinical trials
(excluding trials of investigative medicinal products)
were not being registered and up to 25% of results of
clinical trials of medicines were not being reported [5,
6]. In 2019–2020, efforts were made by the House of
Commons’ Science and Technology Committee to im-
prove clinical trial reporting by NHS trusts and univer-
sities, focusing on the EU Clinical Trials Register
(EU CTR) [7]. However, the EU CTR does not allow
registration of all trial types, so UK universities often use
ClinicalTrials.gov to register certain types of clinical tri-
als, including trials of medical devices. The 2007 Food
and Drug Administration Amendments Act legally re-
quires certain trials involving FDA-regulated drugs and
medical devices to post summary results within 12
months of completion, and the FDA seems to be prepar-
ing to impose financial penalties for non-compliance [8–
10]. The US law only applies to a small minority of trials
sponsored by UK universities that are registered on the
US registry. However, by registering trials on
ClinicalTrials.gov, UK universities have an ethical and
scientific obligation to post the results of those trials on
the registry and keep their registry entries up to date, as
set out in WHO best practices [1]. Indeed, article 36 of
the Helsinki Declaration on Ethical Research Involving
Human Subjects also states that “researchers have a duty
to make publicly available the results of their research
on human subjects and are accountable for the com-
pleteness and accuracy of their reports” [11]. Evidence
suggests that results uploaded on such clinical trial regis-
tries are often more extensive and complete than later
publications [12]. In addition, registry reporting acceler-
ates medical progress by enabling researchers to share
their results rapidly, in advance of publication in a peer
reviewed journal. Even in the absence of legal require-
ments, scientific best practice as defined by the WHO
requires the pre-registration of all trials and the periodic
updating of registry data. The WHO Statement on pub-
lic disclosure of clinical trial results specifies that 12
months is “the longest possible acceptable timeframe for
reporting and shorter timeframes are strongly encour-
aged” [1].
Here, we aimed to develop and verify a tracking tool
that, in contrast to existing trackers, identifies missing
trial results on ClinicalTrials.gov regardless of legal sta-
tus and thus measures trial sponsors’ adherence to glo-
bal best practices rather than their narrow legal
compliance. Our tracker allows all trial sponsors with
interventional trials registered on ClinicalTrials.gov to
easily identify trials that have not yet been fully reported.
Additionally, we aimed to create an overview of unre-
ported trial data on ClinicalTrials.gov for the top Med-
ical Research Council (MRC) funded UK universities
and identify trials sponsored by those universities that
are violating the FDAAA 2007.
Methods
We developed a novel tracking tool, which identifies the
number of interventional clinical trials on ClinicalTrials.
gov with a primary completion date more than 395 days
in the past that have not posted summary results in
tabular format on the registry. The 395-day cut-off point
used to identify due trials includes a 30-day grace period
to allow for review of submitted data by ClinicalTrials.
gov staff after the sponsor has uploaded results. Within
the due trials, we differentiated between those that
remained unreported on the registry, due trials that were
reported late, i.e. after the 395 days cut-off, and due trials
that were reported on time, i.e. within 395 days of the
primary completion date (Fig. 1). Further, we used the
tracker to compare trial status with the primary comple-
tion date to identify trials that may be incorrectly listed
as ongoing, trials with an unknown status, and ongoing
trials lacking a primary completion date, which we clas-
sified as inconsistent. The novel tracking tool has the
following categories, based on which the percentage of
due clinical trials that have not reported their results on
ClinicalTrials.gov in a timely fashion can be calculated.
1. No reporting requirement
All trials that are listed as ’Suspended’ or
’Withdrawn’ are not required to report results.
They are sorted by the tracker to this category even
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if there is inconsistent data (e.g. no primary
completion date) or if they have reported results
(these results are ignored).
2. Due but not reported
Trials that have finished (’Completed’ or
’Terminated’) that have not posted results yet and
have exceeded the reporting timeframe. Trials that
have finished that have not posted results and have
no primary completion dates are also classed under
this category.
3. Due and reported
Trials that have finished (’Completed’ or
’Terminated’) that have reported their results. Late
posting of results will also be in this category.
a) Due and reported late
Trials that have finished (’Completed’ or
’Terminated’) and have reported their results
more than 395 days after their primary
completion date.
b) Due and reported in time
Trials that have finished (’Completed’ or
’Terminated’) and have reported their results
within 395 days.
4. Completed/terminated but not due
a. Results not due yet
Trials that have finished (’Completed’ or
’Terminated’) less than 395 days ago that have
not posted results yet.
b. Results not yet expected but have reported
Trials that have finished (’Completed’ or
’Terminated’) less than 395 days ago but have
reported results.
5. Ongoing
Trials that are ongoing with primary completion
date in the future and have not posted results.
6. Inconsistent data
Trials that are:
Marked as having an 'unknown status'.
Trials that have a completion date in the past
but remain marked as ‘ongoing'
▪ These are trials that should have already
been completed but are self-declaring as on-
going, this is contradictory and therefore
inconsistent.
Ongoing trials that lack a completion date
▪ Trials should have an expected primary
completion date. Not having this is an
inconsistency.
The accuracy of the tracker was manually vali-
dated; the validation methodology and results can be
found in Supplementary File 1. The Github code for
our tracker has been made available freely online
(https://github.com/LeeSean96/GlobalHealthRanking)
and updated results from the tracker will be posted
on the website clinical-trials-tracker.com as a csv file
on a monthly basis alongside a user-friendly inter-
face that is currently undergoing testing and
further development.
Using this novel tracking tool, we assessed the com-
pliance of UK universities with WHO best practices
on results reporting on the US Clinical Trial Registry
(ClinicalTrials.gov) in October 2020. The thirty uni-
versities receiving the largest total 2017-2018 Medical
Research Council (MRC) research grants were se-
lected for analysis [13], which is the latest year for
which this information was available. The tracker also
quantifies the number of days between the primary
completion date and the date that results were pub-
lished on the ClinicalTrials.gov registry, based on
which we calculated the mean and median time delay
for those trials reporting results. Additionally, we uti-
lised the FDAAA Trials Tracker developed by the
Evidence-Based Medicine DataLab at the University of
Oxford to identify any trials sponsored by these UK
universities that are not complying with US disclosure
law (http://fdaaa.trialstracker.net/). We downloaded
the data from ClinicalTrials.gov using our novel
tracking tool on 19 October 2020 and used the
FDAAA Trials Tracker on 28 October 2020.
Fig. 1 A visual overview of the tracker output from the novel US clinical-trials-tracker
Keestra et al. Trials          (2021) 22:375 Page 3 of 7
Results
In October 2020, the thirty UK universities included in
our study were listed as being the lead sponsors of 3034
trials on ClinicalTrials.gov. The University of Oxford
and Imperial College London had the most trials regis-
tered on the US registry, 425 and 390 respectively.
Eleven universities had fewer than fifty trials registered
on ClinicalTrials.gov (Supplementary File 2 shows re-
sults per university). Of all trials sponsored by the thirty
UK universities included in the study cohort, 1634 were
completed and had a primary completion date more
than 395 days in the past. Of these due trials, 26 (1.6%)
had reported results in a timely manner on
ClinicalTrials.gov, adhering to the WHO’s best practice
timeframe of 12 months (Table 1). One hundred forty
trials (8.6%) reported results later than 395 days after the
primary completion date. One thousand four hundred
sixty-eight trials (89.8%) did not report tabular summary
results on the registry (Fig. 2). Furthermore, we found
687 trials (42.0%) containing inconsistent data.
The mean reporting delay after primary completion of
the trials was 981 days (median 728 days) for the clinical
Table 1 Overview of due trials sponsored by thirty UK universities on the ClinicalTrials.gov, sorted according to whether they
reported within the 395 day cut-off, reported late, or did not report at all, as of October 2020. We calculated the percentage of





Late (> 395 days)
reported
Unreported Unreported of all due trials
(%)
Birkbeck, University of London 1 1 100.0
Cardiff University 19 19 100.0
Imperial College London 224 8 79 137 61.2
King's College London 86 4 82 95.3
Liverpool School of Tropical Medicine 6 1 5 83.3
London School of Hygiene and Tropical
Medicine
159 2 7 150 94.3
Newcastle University 17 1 16 94.1
Queen Mary University of London 33 7 26 78.8
Queen's University, Belfast 36 2 34 94.4
St George's, University of London 32 32 100.0
University College London 107 6 101 94.4
University of Aberdeen 44 1 43 97.7
University of Birmingham 35 35 100.0
University of Bristol 10 1 9 90.0
University of Cambridge 33 33 100.0
University of Dundee 70 5 65 92.9
University of Edinburgh 99 1 3 95 96.0
University of Exeter 27 27 100.0
University of Glasgow 37 1 1 35 94.6
University of Leeds 59 2 3 54 91.5
University of Leicester 25 25 100.0
University of Liverpool 20 1 19 95.0
University of Manchester 42 1 1 40 95.2
University of Nottingham 126 2 5 119 94.4
University of Oxford 234 7 11 216 92.3
University of Sheffield 20 20 100.0
University of Southampton 22 1 1 20 90.9
University of Sussex 5 5 100.0
University of Warwick 5 1 4 80.0
University of York 1 1 100.0
Total of all 30 Universities 1634 26 140 1468 89.8
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trials that did report results. The fastest reporting trial was
one by the University of Aberdeen, which reported only
22 days after primary completion date (NCT01245270).
The longest delay in reporting was for a trial at Imperial
College London (NCT00390949) that reported 5943 days
after primary completion.
Only four trials sponsored by UK universities in our study
were in violation of US law FDAAA as of October 2020.
These included one trial reported late by Imperial College
London (NCT03380572) and three studies that remain unre-
ported, sponsored by Imperial College London
(NCT04355156), University of Liverpool (NCT03323229)
and the University of Aberdeen (NCT03770442).
Discussion
As of October 2020, 1468 trials with a primary comple-
tion date more than 395 days in the past that were spon-
sored by the top thirty MRC-funded UK universities
remain without tabular summary results on
ClinicalTrials.gov. There were significant delays to
reporting beyond the 395-day deadline, with a mean of
981 days between trial completion and results posting.
Only 26 (1.6%) trials included in the study reported re-
sults in line with WHO best practices. However, only 4
(0.2%) of the due trials in the cohort are subject to
FDAAA legal disclosure requirements; neither European
Union regulations nor UK national legislation require
summary result posting for the other 1464 trials for
which results were unreported (89.6%) on ClinicalTrials.
gov. Our study therefore suggests the existence of a large
gap between legal and regulatory reporting requirements
and WHO best practices, and weak institutional adher-
ence to the latter [1].
Although only four trials sponsored by our cohort of
UK universities violated FDAAA law in October 2020, it
should be noted that at the time the FDAAA 2007
Fig. 2 Clinical trial reporting performance of thirty UK universities on the US clinical trial registry (ClinicalTrials.gov), differentiated between timely,
late and unreported trials, as of October 2020
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tracker was developed, the law applied to trials con-
ducted after 2017 only. However, following a Federal
Court ruling in February 2020, FDAAA now applies to
trials conducted between 2007 and 2017 as well [14],
something which is not currently reflected in FDAAA
tracker data. It is therefore likely that our analysis
grossly underestimates the extent to which UK univer-
sities are violating legal clinical trial reporting require-
ments. This is especially concerning as the FDA may
fine non-compliant sponsors up to $10,000 for “all viola-
tions adjudicated in a single proceeding” and $11,569 for
each day that a sponsor fails to report results after the
initial 30-day grace period [9]. Although the FDA has so
far failed to levy these fines, this appears to be changing,
and UK universities may face significant financial penal-
ties in the future.
Our study highlights a gap between the registry
reporting performance of UK universities on EU CTR
and ClinicalTrials.gov. Due to public, parliamentary,
and media attention, the existence of applicable
European regulatory guidelines, and the availability
of performance data through the EU Trials Tracker,
the UK academic sector has made very strong pro-
gress on improving results reporting on EU CTR
since late 2018 [15, 16]. Our study suggests that UK
universities have generally not yet extended their
registry reporting efforts to interventional trials listed
on ClinicalTrials.gov, at least not retrospectively,
despite past trials being of great scientific and clin-
ical value as they often involve medical products
already on the market. Retrospectively uploading
data is generally possible, as Imperial College
London demonstrated when they recently managed
to report a trial’s result more than sixteen years after
its primary completion date (NCT00390949, 5943
days overdue). Because of a lack of political and
public pressure, there is currently little incentive for
UK universities to report clinical trial results on the
US registry as well as on EU CTR. Additionally, the
previous lack of a ClinicalTrials.gov equivalent to the
EU Trials Tracker website, which has aided univer-
sities and other trial sponsors in identifying clinical
trials on EU CTR missing results, may have hindered
progress in summary results posting on the US
registry. Finally, we note that although the Inter-
national Committee of Medical Journal Editors
(ICJME) requires the registration of clinical trials on
a primary registry as a condition for publication in
academic journals, it does not require tabular sum-
mary results of trials to be uploaded onto trial regis-
tries [17]. We recommend that the ICJME expands
its current policy to require summary results to be
uploaded onto a trial registry before a paper is con-
sidered for publication in an academic journal,
thereby incentivising routine adherence to scientific
best practices as set out by the WHO.
The validity of our findings has been assured by the
rigorous manual validation of the tracking tool. Our
findings and tracker can be used to analyse reporting
compliance on ClinicalTrials.gov and allow all trial spon-
sors to identify missing trial results. Of note, poor results
reporting is not a problem unique to UK universities
and a global analysis of missing trial results on the US
registry would be useful as a means to highlight the per-
formance of particular countries or institutions to ensure
WHO best practices on clinical trial transparency are
adhered to and to help guide policy development.
A limitation of our current study is that we were un-
able to determine the extent of the possible overlap be-
tween the US and the EU clinical trial registry, which
could explain the poor performance of UK universities
on ClinicalTrials.gov. However, we strongly believe that
through trial registration on the US registry, sponsors
are committing to keeping their trial status up to date
and uploading results in accordance with WHO require-
ments, even if they register a clinical trial on two regis-
tries at the same time. Thus, even if a trial has been
reported elsewhere, for example in the academic litera-
ture or on another primary registry, this does not ex-
empt trial sponsors from the ethical commitment to
update the details of their trial on ClinicalTrials.gov as
well.
Conclusion
Many major universities and hospitals across the Euro-
pean Union are currently working to improve their clinical
trial reporting on EU CTR. Our findings raise concerns
that these efforts may apply only to the small minority of
trials involving investigative medicinal products that are
registered on EU CTR, which are subject to reporting re-
quirements under the EU Clinical Trial Regulation. Our
findings suggest that non-commercial trial sponsors are
not yet adopting WHO best practices in reporting the re-
sults of trials that cannot be registered on EU CTR. Such
trials greatly outnumber trials of investigative medical
products, and can be of equal or greater scientific and
clinical importance; across Europe, they are most com-
monly registered on ClinicalTrials.gov, but also on other
WHO primary registries such as ISRCTN and DRKS.
Governments, regulatory agencies and research funders
worldwide should extend registry reporting requirements
to all interventional clinical trials as per WHO best prac-
tices [18]. We hope that our novel US clinical trials track-
ing tool (clinical-trials-tracker.com) will drive trial
sponsors worldwide to exceed narrow regulatory compli-
ance and fully implement WHO best practices to improve
the completeness and accuracy of the medical evidence
base and accelerate medical progress.
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The scientific community is currently under immense
pressure not only to produce novel health technologies for
COVID-19, but also to prove rapidly and rigorously that
they are safe and effective. The scrutiny of the transpar-
ency of clinical trial results for COVID-19 related health
technologies should apply across the health sector, with
detailed, timely and accurate reporting of clinical trials be-
coming the norm in order to facilitate evidence-based
medicine during the pandemic and beyond.
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